PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33746212-9	2021	In subgroup 2, mOS from progression on docetaxel increased from 7.9 months to 12.5 months (p < 0.001).	Docetaxel	39-48	Moloney sarcoma oncogene	Mus musculus	15-18	
34976813-14	2021	Also, SCA plus DOX can significantly improve OS and exerted a significant synergistic effect, with good safety and tolerance profile.	Docetaxel	15-18	Moloney sarcoma oncogene	Mus musculus	45-47	
34084103-11	2021	Compared with the docetaxel plus platinum group, the gemcitabine plus platinum group had significantly higher RR (71.4% vs. 52.6%, P < 0.05); mPFS (9.7 vs. 7.8 months, P < 0.05), and mOS (20.6 vs. 16.8 months, P < 0.01).	Docetaxel	18-27	Moloney sarcoma oncogene	Mus musculus	183-186